Analysts see LLY reaching $1,500 within a year after 19% weight-loss data and four consecutive EPS beats boosted shares to 52-week highs.
Eli Lilly shares surged to a 52-week high after retatrutide delivered 19% weight-loss results in Phase 3 trials, outpacing AstraZeneca’s elecoglipron. The stock, trading at $1,149.15, has climbed 50.31% over the past year but only 7.29% year-to-date due to China pricing concerns and $584M in IPR&D charges.
TD Cowen projects LLY will capture 62% of the $150 billion GLP-1 market by 2030, with four directors buying shares near $950 this spring. Competitive pressure from AZN’s elecoglipron, which showed 11.8% weight loss, has not slowed momentum, though 340B restrictions and earnings volatility remain risks.
The stock’s beta of 0.517 suggests recent volatility stemmed from earnings noise rather than broader market trends. Analysts view retatrutide’s data as potentially first-line for obesity, reinforcing LLY’s leadership in the GLP-1 space.